Peptech seeking new CEO
Tuesday, 05 March, 2002
Sydney biotech Peptech is on the hunt for a new CEO.
In a statement to the Australian Stock Exchange, Peptech chairman Dr Ed Tweddell said that the worldwide search came after a review of the company's future growth prospects.
Current managing director Stephen Kwik will remain at Peptech to help with the search.
"It may take six months to have the new person in position, but we are focused on our goals and will continue to progress our initiatives in the interim," Tweddell said.
"Stephen's experience will be valuable over the next six months in bolting down the licence and royalty agreements under the recently issued US patent for TNF antibodies."
Tweddell said that recent restructuring, which included the departure of Graham Mitchell and the appointment of John Leaver, had strengthened the Peptech board.
Peptech had also consolidated its relationship with UK company Diversys, he said.
"The company is positioned for growth both in regard to royalty income and in being able to capitalise on business development opportunities both in Australia and overseas," Tweddell said.
CTA granted for CAR-T cell therapy for multiple myeloma
The Therapeutic Goods Administration has granted Clinical Trial Approval for KMCAR T-cell...
2026 Snow Fellowship recipients to receive $24m in biomedical funding
Australian biomedical researchers Dr Deborah Burnett, A/Prof Sudarshini Ramanathan and Dr Ira...
$780m Sydney Biomedical Accelerator gains its founding Executive Director
Professor Victoria Cogger has been appointed as founding Executive Director of the Sydney...
